I don't expect the med-tech sector to match the performance of 2013 this year, but I continue to believe that Novadaq (NVDQ) will be a market-beater. Novadaq has only just begun to show what its imaging technology can do in terms of clinical results, market share, and revenue. As time goes on, I expect this company to be one of the most impressive growth stories in med-tech, and a stock well worth owning.
PINPOINTing The Opportunity
A lot of Novadaq's future rides on the success of its PINPOINT endoscopic fluorescence imaging system ("Pinpoint"). As the name might suggest, this is an endoscopic system that allows surgeons to visualize anastomoses and perfusion during minimally invasive procedures. Insufficient bloodflow...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: